INTRODUCTION
============

As increase of the concern in the functional food and well being in life, the demands and consumption of functional food originated form natural sources are increased [@B018]. However, the toxicological aspects about these natural origin-functional foods has been neglected because of the reasons that they has been used as various purpose for long times. Therefore, it is considered that more detailed and systemic toxicological studies should be performed to control the abuse and potential toxicities even if they have been used as traditional folk medicine [@B025].

Bone marrow cytogenetics, micronucleus test is a useful short-term technique for elucidating the mechanism as well as to identify the substances for their clastogenic and anticlastogenic activity [@B024]. In [@B013], the genotoxicity should be tested prior to develop a new drug even though they have natural origin. Most of natural herbal agents, genotoxicity has been performed using *in vivo* like micronucleus test [@B012]; [@B025].

A traditional Korean herbal medicine, Picrorrhiza Rhizoma (PR) is a dried root and stem of *Picrorrhiza kurroa*, and has been traditionally used as hepatoprotective agents such as jaundice [@B014]. Until now, the nitric oxide scavenging activity [@B009], cardioprotective effect [@B027], anti-cancer effect [@B011], anti-diabetic activity [@B010], anti-viral effect [@B020], immunostimulatory or immunomodulatory effects [@B028], hypolipidemic and hepatoprotective effects [@B017], nephroprotective effects [@B014], anti-inflammatory effects [@B016]; [@B023] of PR extracts have been evaluated with single mouse oral dose toxicity [@B015]. However, there are no reports dealing the potential genotoxicity of PR extract upon our knowledge. The objective of the present study, therefore, was to obtain the genotoxic information about PR extracts, lyophilized water extract of *Picrorrhiza kurroa*,and further clarify their safety for clinical use.

MATERIALS AND METHODS
=====================

***Animals and husbandry.*** Fifty male ICR mice (6-wk old upon receipt, SLC, Japan) were used after acclimatization for 10 days. The body weights of animals at receipt are ranged in 28\~32 g. Animals were allocated five per polycarbonate cage in a temperature (20\~25℃) and humidity (30\~35%) controlled room. Light : dark cycle was 12 h : 12 h and feed (Samyang, Korea) and water were supplied free to access. Animals were marked by picric acid. This study was carried out with prior approval of the Animal Ethical Committee, The University of Daegu Haany University (Gyeongsan, Korea).

***Test articles and formulation.*** Aqueous PR extracts (absorption rate 25.63%) were prepared by routine methods using rotary vacuum evaporator (Lab. Camp, Korea) and programmable freeze dryer (IlShin Lab., Korea) from PR, which were purchased from Cho-Heung Pharmaceutical Ind. Co. (Daegu, Korea) after confirm the morphology under microscopy. Powders of PR extracts are deep brown powder. PR extracts were stored in a refrigerator at −20℃ to protect from light and degeneration. The appearance of PR extracts in vehicle is clear deep brown solution in distilled water and it is well soluble upto 200 mg/m*l* concentration levels. The test article was orally administered at a dosage volume of 10 m*l*/kg, once a day for 2 days by oral gavage to mice; total 2000, 1000 and 500 mg/kg using distilled water as vehicle. Cyclophosphamide·H~2~O (CPA; Sigma, USA) was used as an identified genotoxic agents in a positive control group. CPA was dissolved in saline and once intraperitoneally administered at a volume of 10 m*l*/kg (70 mg/kg)

***Grouping and dosing.*** The animals were allocated into five groups 10 mice each. The fixed highest dosage level of 2000 mg/kg oral dosing was chosen in accordance to the results of single oral dose toxicity test [@B015], in which no PR extract treatment-related toxicological evidences were detected upto 2000 mg/kg, the limited highest dosage in rodent recommended by KFDA guidelines (2009), and 500 and 250 mg/kg was selected using the common ratio 2. Control negative (taken vehicle) and control positive (CPA; 70 mg/kg-single treatment) were included by recommendation of [@B013] and [@B022].

***Observation of clinical signs.*** All abnormal clinical signs were recorded before and after dosing at least twice a day based on the functional observational battery test [@B002]; [@B008].

***Body weight changes.*** Body weights were measured once a day.

***Bone marrow preparation.*** All animals were sacrificed 24 h post administration using carbon dioxide, and bilateral femur was separated. Bone marrow preparations were made according to [@B026]. In brief, bone marrow cells were collected from aforementioned femur in 3 m*l* of inactivated fetal bovine serum (Gibco BRL, USA), centrifuged, and smeared on slides. Preparations were dried, and fixed by submerging in absolute methanol (for 10\~20 min). Fixed slides were stained as follows;

1.  May-Grunwald stain 3 min

2.  May-Grunwald stain (1 : 1 diluted) 2 min

3.  Giemsa stain (1 : 6 diluted) 10 min

![Representative cytology of bone marrow cell smears. In prepared bone marrow cell smear, polychromatic erythrocyte (PCE), normochromatic erythrocyte (NCE), PCE with one or more nuclei (MNPCE) were counted based on the above morphology. NCE containing nucleus (MNNCE) was not calculated. Although, significant (p \< 0.01) increase of MNPCEs was detected in CPA 70 mg/kg, no significant changes on MNPCE numbers were detected in all three different PR extract treated groups tested as compared with vehicle control. In addition, the PCE ratio was detected above 0.43 (in individual mice, over 0.39) in all tested groups including negative and positive control in this study. Scale bars = 10 μm.](toxicr-27-119-g001){#F001}

***Observation and recoding of micronuclei.*** Slides were randomly coded and examined under × 1000 magnification by two different experts. Small round or oval shaped bodies, size of which ranging from 1/5 to 1/20 diameter of polychromatic erythrocytes (PCE), were counted as micronuclei (MN). Attention was given to discriminate micronuclei from artifacts ([Fig 1](#F001){ref-type="fig"}). Results were expressed as the number of MNPCEs in 2000 PCEs. Mean number of MNPCE ± standard deviation was calculated for each treatment group. In addition, PCE ratio (PCE/(PCE + normochromatic erythrocytes (NCE)) ratio were also calculated by counting 1000 erythrocytes, for detecting the possibility of cytotoxicity [@B007].

***Statistical analyses.*** Multiple comparison tests for different dose groups were conducted. Variance homogeneity was examined using the Levene test. If the Levene test indicated no significant deviations from variance homogeneity, the obtain data were analyzed by one way ANOVA test followed by the Scheffe test to determine which pairs of group comparison were significantly different. In case of significant deviations from variance homogeneity were observed at Levene test, a non-parametric comparison test, the Mann-Whitney U test was conducted to determine the specific pairs of group comparison. The result of statistical evaluation was regarded significantly when the P value was less than 0.05. In addition, the study was accepted when all of the PCE ratio are greater than 0.20 [@B007]. Statistical analyses were carried out using SPSS for Windows (Release 14.0K, SPSS Inc., USA).

RESULTS
=======

***Mortalities.*** No test article-treatment related unscheduled mortalities were detected in all tested doses during the observation periods.

***Clinical signs.*** During the observation period, no abnormal clinical signs were observed from PR extract treatment.

###### 

Changes on the body weights

  ---------------- ------------------ ------------------ --------------
  Groups           Day after dosing                      
                                                         
  Day 0^1)^        Day 1              At a termination   
                                                         
  Intact control   36.33 ± 1.30       41.07 ± 1.37       36.97 ± 1.30
  CPA control      37.02 ± 1.41       41.30 ± 1.21       37.34 ± 1.53
  PR extract                                             
  2000 mg/kg       36.94 ± 1.84       40.97 ± 1.92       37.60 ± 1.57
  1000 mg/kg       36.09 ± 2.19       40.61 ± 3.12       37.14 ± 2.57
  500 mg/kg        36.78 ± 2.95       40.56 ± 2.59       37.51 ± 2.97
  ---------------- ------------------ ------------------ --------------

^a^Values are expressed as mean ± SD, g of ten mice.

^1)^Start day of test article administration.

All animals were overnight fasted at Day 0 and a termination, respectively.

###### 

Changes on MNPCE numbers and PCE/(PCE + NCE) ratio observed in mice

  ------------------- ------------------- ----------------- ------------
  Group               MNPCEs/ 2000 PCEs   PCE/(PCE + NCE)   
                                                            
  Ratio               Range                                 
                                                            
  Intact control      1.10 ± 0.99         0.43 ± 0.03       0.40\~0.50
  CPA control         64.00 ± 11.12^\*^   0.41 ± 0.02       0.39\~0.43
  DHU001 2000 mg/kg   0.90 ± 0.99         0.44 ± 0.02       0.40\~0.48
  DHU001 1000 mg/kg   0.80 ± 0.79         0.43 ± 0.02       0.40\~0.49
  DHU001 500 mg/kg    1.00 ± 0.82         0.45 ± 0.05       0.39\~0.54
  ------------------- ------------------- ----------------- ------------

Values are expressed as mean ± SD of ten mice.

PCE, polychromatic erythrocyte, MN, micronuclei, NCE, normochromatic erythrocyte.

PCE+NCE=1000 erythrocytes.

^\*^ p \< 0.01 compared with intact control by Mann-Whitney U test.

***Body weight changes.*** No meaningful changes on body weights were detected in CPA and all tested doses of PR extract treated groups as compared to that of control negative group (taken vehicle only) ([Table 1](#T001){ref-type="table"}).

***Changes on MNPCE numbers and PCE ratio.*** Significantly (p \< 0.01) increase of number of MNPCEs among 2000 PCEs was detected in CPA 70 mg/kg a positive control group. However, no significant changes on MNPCE numbers were detected in all three different PR extract treated groups tested as compared with vehicle control. The PCE ratio in total 500 erythrocytes was detected above 0.43 (in individual mice, over 0.39) in all tested groups including negative and positive control ([Fig. 1](#F001){ref-type="fig"}, [Table 2](#T002){ref-type="table"}).

DISCUSSION
==========

In the present study, the genotoxic effects of PR extracts were evaluated using the mouse micronucleus test. As the results obtained in the present study, PR extract shows no genotoxicity effect up to 2000 mg/kg dosing levels. The highest dosage used in the present study was selected as 2000 mg/kg oral dosing was chosen in accordance to the results of single oral dose toxicity test [@B015], in which no PR extract treatment-related toxicological evidences were detected upto 2000 mg/kg, the limited highest dosage in rodent recommended by KFDA guidelines (2009), and vehicle and positive control were added according to the recommendation of KFDA (2009) and OECD (1997) guidelines.

Micronucleus assays were first introduced in the early 1970\'s for the examination of genotoxic activity of chemical agents [@B005]; [@B019]. The procedure is based on the observation that mitotic cells with chromatid breaks or incomplete exchanges or with malfunction of the spindle apparatus suffer from disturbances in anaphase distribution of their chromatin. After telophase, a sizable portion of this displaced chromatin is not included in the nuclei of the daughter cells but forms single or multiple micronuclei in the cell cytoplasm. The frequency of the appearance of micronuclei depends both upon the rate of chromosome breakage or loss and the rate of cell division [@B007]; [@B029]. Although micronuclei can occur in almost all dividing cells, mouse bone marrow is usually the tissue used for the micronucleus test, and any agent which induces chromosomal aberrations can also produce micronuclei [@B006], [@B007].

Because of its simplicity and efficacy, the micronucleus test has become a popular and useful in vivo procedure for the detection of chemically-induced chromosome damage. The number of reports from micronucleus testing has increased dramatically in the scientific literature during the past decade [@B001], and the value of this test for examining the mutagenicity and carcinogenicity of chemicals has been emphasized, particularly when it is used in combination with other cytogenetic assays [@B007].

The PCE ratio was used as index of cytotoxicity and the study was accepted when all of the PCE ratio are greater than 0.20 [@B007]. The PCE ratio was detected as \> 0.43 in all tested groups including negative and positive control in the present study. That is no problem from cytotoxicity of the tested articles used in this work.

CPA is a widely used anti-neoplasic drug, employed either alone or in combination with other products [@B004]. The parent drug is biologically inactive, however after biotransformation by microsomal enzymes a number of active metabolites capable of alkylating nucleic acids [@B021], damage the chromosomes (through generation of free-radicals) and/or alkylating the DNA thereby producing mutagenicity [@B003] were produced. In the present study, CPA used as a positive control, and it showed a significant increases of MNPCE ratios. This indicates that the experiment protocol and the results of the present study are acceptable, and no meaningful increases of MNPCE were reported up to 2000 mg/kg of PR extract.

Based on the results, it is concluded that PR extract shows no genotoxicity and immunosuppress effects up to 2000 mg/kg dosing levels. In addition, it is also considered that there were no problems from cytotoxicity of PR extract because the polychromatic erythrocyte ratio was estimated as \> 0.43 in all tested groups (in individual mice, over 0.39).
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